Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MInfla-Tilc

Financiado

Generation of therapeutic antibodies targeting type 2 Innate Lymphoid cells in a...

We are proposing to target Innate Lymphoid Cells 2 (ILC2s), a subset that has been frequently implicated in inflammatory diseases, such as severe asthma. ILC2s are major players in allergic asthma and are abundantly present as tis... ver más

31/12/2021

AMU

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITE DAIX MARSEILLE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

AMU

150.00K€ | Lider

LABORATORIOS CONDA

211.80K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 24 meses Fecha Inicio: 2019-12-06
Fecha Fin: 2021-12-31

Líder del proyecto

UNIVERSITE DAIX MARSEILLE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto We are proposing to target Innate Lymphoid Cells 2 (ILC2s), a subset that has been frequently implicated in inflammatory diseases, such as severe asthma. ILC2s are major players in allergic asthma and are abundantly present as tissue resident cells in the lung, both in human and mouse. Strikingly, the induction of allergic asthma in a mouse model deficient in ILC2s is abolished. In addition, the transfer of ILC2s back in the same mouse recapitulates the pathology. Mechanistically, activated ILC2s are the main producer of type 2 cytokines that sustain the chronicity of asthma by recruiting other inflammatory and pathogenic cells, notably eosinophils, and finally drive hyperresponsiveness and mucous hypersecretion. In humans, ILC2s are increased in the peripheral blood mononuclear cells (PBMCs) of patients with allergic asthma compared to healthy controls. They are also found in sputum and PBMCs of patients with severe, eosinophilic asthma compared to mild forms of asthma. Collectively, these data highlight the significance of ILC2s in allergic inflammation and emphasize the idea to target those cells for therapeutic purposes. MInfla-Tilc is a translational and integrated project aiming to launch an innovative therapeutic monoclonal antibody (mAb) treatment against ILC2s to control severe asthma.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores